Use of natural killer (NK) cells carrying an anti-spike mAb as covid19 therapy

Key facts

Disease
COVID-19
Funder
ANR
Principal Investigator
Martin VILLALBA
Research Location
France
Lead Research Institution
CHRU de Montpellier
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

The CoviNK project, coordinated by Martin Villalba (UMR U1183 Institute of Regenerative Medicine and Biotherapies (IMRB) - CHRU de Montpellier), proposes to use natural killer cells (NK) carrying an anti-spike mAb, for the treatment of COVID -19. The team will be based on an expanded NK (eNK) production protocol patented by Inserm, and on a new approach for stably loading monoclonal antibodies (mAbs) on the membrane of NK cells, currently being developed for the cancer therapy.

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.